Windtree Therapeutics, dubbed the "BNB MicroStrategy" company, received notification from NASDAQ on August 19, 2025, that its common stock will be delisted from the NASDAQ Capital Market on August 21 due to failure to meet the minimum closing price maintenance standards under Rule 5550(a)(2). The stock will subsequently transfer to OTC market trading.
Previously, the company had announced plans to raise up to $520 million through equity financing, with 99% of the proceeds intended for purchasing BNB.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。